Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-x <sub>L</sub> from NMR and Parallel Synthesis
Andrew M. Petros(Abbott Fund), Stephen W. Fesik(Vanderbilt University), Steven A. Baumeister(Abbott Fund), Irini Zanze(Abbott Fund), David G. Nettesheim(Abbott Fund), David A. Betebenner(Abbott Fund), Xilu Wang(AbbVie (United States)), Shelley K. Landis(Abbott Fund), Mark G. Bures(Abbott Fund), Shen Wang(Abbott Fund), Haichao Zhang(Abbott Fund), Sheela A. Thomas(Abbott Fund), Steven W. Elmore(AbbVie (United States)), Mary K. Joseph(Abbott Fund), Saul H. Rosenberg(AbbVie (United States)), David J. Augeri(Abbott Fund), Philip J. Hajduk(Abbott Fund), Jürgen Dinges(Abbott Fund)
Cited by 293
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k